Trial Profile
An International, Multi-Center, Randomized, Open-Label Study of PS-341 [bortezomib] (VELCADE) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms APEX
- Sponsors Millennium
- 13 Dec 2022 Results by deriving gene expression profiles from APEX; assessing whether increased expression of genes PSMC2 and PSMC6, correlated with poorer OS , presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 12 Jan 2012 Status of the extension trial (NCT00063726) is completed.
- 12 Jan 2012 Status of the extension trial (NCT00063726) is completed.